Online citations, reference lists, and bibliographies.

Malignant And Borderline Mesothelial Tumors Of The Pleura

M. R. Wick, K. Leslie, J. Ritter, S. Mills
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Abstract This chapter considers the clinicopathologic features of borderline and malignant mesothelial pleural neoplasms. They include “well-differentiated papillary mesothelioma,” multicystic mesothelial tumors of borderline biological potential, and malignant mesotheliomas. The specialized morphological features of those lesions are discussed, with emphasis on differential diagnosis with other tumors.
This paper references
10.1043/0003-9985(2001)125<1316:IAONVC>2.0.CO;2
Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas.
M. Foster (2001)
10.1053/HUPA.2000.9843
Distribution of keratins in normal endothelial cells and a spectrum of vascular tumors: implications in tumor diagnosis.
M. Miettinen (2000)
10.1111/j.1699-0463.1997.tb05099.x
Optimization of a battery using nine immunocytochemical variables for distinguishing between epithelial mesothelioma and adenocarcinoma
A. Dejmek (1997)
10.1097/00005382-200307000-00011
Pseudomesotheliomatous angiosarcoma of the chest wall and pleura.
C. del Frate (2003)
10.3109/01913129409016288
Ultrastructure of adrenal cortical carcinoma.
B. Mackay (1994)
10.1002/path.1711750210
Detection of numerical chromosomal aberrations in paraffin-embedded malignant pleural mesothelioma by non-isotopic in situ hybridization.
K. Segers (1995)
10.1053/RMED.2001.1178
Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics.
M. Metintas (2001)
10.1016/S1092-9134(03)00078-9
Current controversies regarding the role of asbestos exposure in the causation of malignant mesothelioma: the need for an evidence-based approach to develop medicolegal guidelines.
A. Marchevsky (2003)
10.1097/00001622-200303000-00003
The role of new imaging techniques in diagnosis and staging of malignant pleural mesothelioma
R. Eibel (2003)
10.1002/cncr.10923
The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions
P. Illei (2003)
p53 gene mutations in asbestos associated cancers.
B. Liu (1998)
10.1093/AJCP/110.3.397
Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review.
D. Henderson (1998)
The asbestos dilemma: I. Assessment of risk.
F. Valić (2002)
10.1097/00000478-198810000-00002
Three Types of Spindle Cell Tumors of the Pleura: Fibroma, Sarcoma, and Sarcomatoid Mesothelioma
D. Carter (1988)
10.1097/01.MP.0000083647.69123.5C
c-Kit Is Not Expressed in Malignant Mesothelioma
A. Horvai (2003)
10.1016/S0046-8177(00)80194-X
Malignant epithelioid vascular tumors of the pleura: report of a series and literature review.
P. Zhang (2000)
10.1080/01913120500313143
Macroscopic, Histologic, Histochemical, Immunohistochemical, and Ultrastructural Features of Mesothelioma
S. Hammar (2006)
10.3109/01913129109016250
The diagnosis of thymoma: a review.
E. Hammond (1991)
10.5555/uri:pii:074025709290008W
The concept of mesothelioma in situ: implications for diagnosis and histogenesis.
D. Whitaker (1992)
10.1097/01.MP.0000056981.16578.C3
Value of Mesothelin Immunostaining in the Diagnosis of Mesothelioma
N. Ordóñez (2003)
10.1309/NL4Y-FHG8-2XBC-F9XH
The value of thyroid transcription factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin.
J. Hecht (2001)
10.1016/s0022-5223(19)35312-7
The role of computed tomography scanning in the initial assessment and the follow-up of malignant pleural mesothelioma.
V. Rusch (1988)
10.1043/1543-2165-133.7.1106
Update in neoplastic lung diseases and mesothelioma.
Ilyssa O. Gordon (2009)
10.1111/J.1440-1843.1997.TB00079.X
A case of malignant pleural mesothelioma following exposure to atomic radiation in Nagasaki.
M. Mizuki (1997)
Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis.
S. Breiteneder-Geleff (1997)
10.1016/0046-8177(94)90115-5
p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens.
P. Cagle (1994)
10.1111/J.1440-1827.2007.02148.X
D2-40-positive solitary fibrous tumors of the pleura: diagnostic pitfall of biopsy specimen.
Y. Naito (2007)
10.1097/00063198-200007000-00003
Management of malignant pleural mesothelioma: a critical review
Y. Lee (2000)
Homozygous deletions within 9p21-p22 identify a small critical region of chromosomal loss in human malignant mesotheliomas.
J. Cheng (1993)
10.1136/JCP.54.10.766
Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry.
F. Roberts (2001)
[Cytodiagnosis in lung diseases. Its importance and its value. A study of 945 cases].
G Castelain (1968)
10.1111/j.1365-2559.2008.03099.x
The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma.
R. Attanoos (2008)
10.1097/01.pas.0000165529.78945.dc
Localized Malignant Mesothelioma
T. Allen (2005)
Biological and immunological aspects of malignant mesothelioma.
M. Garlepp (1995)
10.1016/0092-8674(90)90690-G
An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor
D. Haber (1990)
10.1016/j.canlet.2016.05.011
CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma.
M. Betti (2016)
10.1043/1543-2165(2005)129[1407:IDOEMA]2.0.CO;2
Immunohistochemical diagnosis of epithelioid mesothelioma: an update.
N. Ordóñez (2005)
10.1080/019131299281383
Glycogen-rich mesothelioma.
N. Ordóñez (1999)
10.1371/journal.pone.0010612
Second Generation Sequencing of the Mesothelioma Tumor Genome
R. Bueno (2010)
10.1136/jcp.52.4.291
Mutations of p53 gene and SV40 sequences in asbestos associated and non-asbestos-associated mesotheliomas.
F. Mayall (1999)
10.1093/jnci/52.6.1715
Ultrastructure of human mesotheliomas.
J. Davis (1974)
Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3.
A. Thor (1986)
10.1016/S1567-5769(01)00170-9
Diseases caused by silica: mechanisms of injury and disease development.
M. Ding (2002)
Malignant rhabdoid tumors: a clinicopathologic review and conceptual discussion.
M. Wick (1995)
10.1097/00000478-198505000-00006
Immunohistochemical staining for vimentin and keratin in malignant mesothelioma
A. Churg (1985)
10.1053/HUPA.2002.130104
Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma.
S. Lau (2002)
10.1136/jclinpath-2016-203866
Gene of the month: BAP1
Ami Wang (2016)
10.1097/PAS.0000000000000200
Well-differentiated Papillary Mesothelioma With Invasive Foci
A. Churg (2014)
[Distribution of thrombomodulin in human tissues and characterization of thrombomodulin in plasma].
Hisato Ishii (1988)
Histochemistry in the diagnosis of malignant mesothelioma.
M. Kannerstein (1973)
10.1046/J.1365-2559.2001.01136.X
p27 immunostaining is related to prognosis in malignant mesothelioma.
T. Beer (2001)
Malignancies in the lung and pleura mimicking benign processes.
Colby Tv (1995)
10.1016/0959-8049(95)00574-9
Well-differentiated papillary mesothelioma of the peritoneum: a separate entity.
K. Hoekman (1996)
10.1097/00000478-200004000-00016
Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma.
N. Ordóñez (2000)
10.1111/j.1365-2559.1992.tb00403.x
p53 expression is common in malignant mesothelioma.
G. Kafiri (1992)
Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma.
D. Jordon (1989)
The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance.
G. Blobel (1985)
10.1016/j.jtho.2015.11.005
The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.
F. Galateau-Sallé (2016)
10.1080/0913120290104647
Deciduoid Mesothelioma: A Report of 5 Cases and Literature Review
J. Shia (2002)
10.1016/0046-8177(91)90292-W
Atypical mesothelial hyperplasia associated with bronchogenic carcinoma.
T. Yokoi (1991)
10.1007/BF02982573
The Role of WT1 in Oncogenesis: Tumor Suppressor or Oncogene?
D. Loeb (2002)
10.1634/THEONCOLOGIST.4-6-488
Contemporary management of malignant pleural mesothelioma.
E. Butchart (1999)
10.1002/1097-0142(19861015)58:8<1699::AID-CNCR2820580820>3.0.CO;2-B
Thrombocytosis in patients with malignant pleural mesotheliomia
T. Nakano (1986)
10.1016/j.biochi.2009.11.004
Neurotensin expression and outcome of malignant pleural mesothelioma.
Marco Alifano (2010)
10.1016/j.ejcts.2007.09.045
PTEN expression is a strong predictor of survival in mesothelioma patients.
I. Opitz (2008)
10.1016/S1010-7940(02)00273-7
The management of malignant pleural mesothelioma; single centre experience in 10 years.
T. Aziz (2002)
10.3109/01913129609016333
Clear cell mesothelioma.
N. Ordóñez (1996)
10.1097/00125480-199801000-00052
Calretinin: a novel tool for diagnostic immunohistochemistry.
A. D. Dei Tos (1998)
10.1097/00000478-198908000-00010
Sarcomatous tumor of the chest wall with osteochondroid differentiation. Evidence of mesothelial origin.
A. Andrion (1989)
10.1038/bjc.1998.150
Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.
T. Nakano (1998)
10.1007/BF01247458
Mesothelioma-like tumors of the pleura: a review of 72 autopsy cases
C. Hartmann (2005)
10.3109/01913128909057439
Ultrastructural and immunocytochemical observations on angiosarcomas.
B. Mackay (1989)
10.1046/J.1365-2559.2001.01157.X
Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura.
C. González-Lois (2001)
10.1016/j.anndiagpath.2009.10.005
Plasma cell myeloma presenting with diffuse pleural involvement: a hitherto unreported pattern of a new mesothelioma mimicker.
Antonio Colonna (2010)
10.1002/DC.20486
The high post‐test probability of a cytological examination renders further investigations to establish a diagnosis of epithelial malignant pleural mesothelioma redundant
J. Aerts (2006)
Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression.
Maria E. Ramos-Nino (2002)
Malignant mesotheliomas with osseous and cartilaginous differentiation.
S. Yousem (1987)
10.1002/9781444300109.ch49
Lung, Pleura, and Mediastinum
L. Tao (1988)
10.1016/0046-8177(93)90080-Z
Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
R. Brown (1993)
10.1043/1543-2165(2008)132[1062:IOPAPN]2.0.CO;2
Immunohistochemistry of pulmonary and pleural neoplasia.
M. Beasley (2008)
10.1053/j.semtcvs.2009.06.005
Pathologic evaluation of malignant pleural mesothelioma.
L. Chirieac (2009)
10.1053/HUPA.2001.28226
Extraskeletal myxoid chondrosarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of 18 cases.
S. Okamoto (2001)
10.1038/sj.onc.1205203
SV40 infection induces telomerase activity in human mesothelial cells
R. Foddis (2002)
10.1007/BF00734635
Ultrastructural aspects of the histogenesis of diffuse and localized mesothelioma
I. Dardick (1984)
10.1097/00000478-198204000-00003
Desmoplastic diffuse mesothelioma
R. Cantin (1982)
10.1016/0046-8177(90)90036-5
Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural, and immunohistologic study of 103 cases.
M. Wick (1990)
10.1007/s12199-007-0015-8
Molecular biology of malignant mesothelioma
Y. Sekido (2008)
10.1002/1097-0142(20010901)92:5<1245::AID-CNCR1444>3.0.CO;2-G
p27kip1 immunoreactivity correlates with long‐term survival in pleural malignant mesothelioma
M. Bongiovanni (2001)
10.1046/J.1365-2559.2000.00793.X
MIB-1 proliferation index correlates with survival in pleural malignant mesothelioma.
C. Comin (2000)
10.1111/pin.12453
BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests.
T. Hida (2016)
10.1136/jcp.45.4.295
Desmoplastic malignant mesothelioma: a review of 17 cases.
G. Wilson (1992)
Pathogenesis of Mesothelioma
B. Mclaren (2002)
10.1111/j.1365-2559.1992.tb00915.x
The histology and immunohistochemistry of small cell mesothelioma.
F. Mayall (1992)
10.1097/00000478-200302000-00002
Expression of Calretinin, Thrombomodulin, Keratin 5, and Mesothelin in Lung Carcinomas of Different Types: An Immunohistochemical Analysis of 596 Tumors in Comparison With Epithelioid Mesotheliomas of the Pleura
M. Miettinen (2003)
10.1038/modpathol.3800534
Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity
H. Yaziji (2006)
10.2105/AJPH.81.12.1661
Epidemiology and the law: courts and confidence intervals.
T. Christoffel (1991)
The distinction of mesothelioma from adenocarcinoma in malignant effusions by electron microscopy.
L. Kobzik (1985)
10.1053/HUPA.2001.24329
Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
C. Comin (2001)
10.1097/PAI.0b013e3181b91a51
Immunohistochemical Study as a Tool in Differential Diagnosis of Pediatric Malignant Rhabdoid Tumor
Isidro Machado (2010)
[Different localization of thrombomodulin].
Marie Claire Boffa (1987)
10.1016/1010-7940(89)90056-0
The diagnosis, therapy and prognosis of diffuse malignant mesothelioma.
R. Achatzy (1989)
10.1053/SONC.2002.30228
The role of imaging in malignant pleural mesothelioma.
E. Marom (2002)
10.1093/milmed/144.7.476
Psammoma bodies in pleural fluid associated with a mesothelioma: case report.
Donaldson Jc (1979)
10.1046/J.1440-1827.2001.01250.X
Localized malignant mesothelioma of the pleura.
H. Okamura (2001)
10.3109/01913128309140587
Sarcomatous type of malignant mesothelioma.
M. Klima (1983)
10.1111/j.1440-1827.2008.02301.x
Pulmonary epithelioid hemangioendothelioma mimicking mesothelioma.
Armita Bahrami (2008)
10.1097/01.MP.0000052103.13730.20
Hep Par 1 Antibody Stain for the Differential Diagnosis of Hepatocellular Carcinoma: 676 Tumors Tested Using Tissue Microarrays and Conventional Tissue Sections
Z. Fan (2003)
10.5858/arpa.2012-0112-ra
The Separation of Benign and Malignant Mesothelial Proliferations
A. Churg (2012)
10.1016/0046-8177(91)90032-K
Expression of blood group-related antigens and Helix pomatia agglutinin in malignant pleural mesothelioma and pulmonary adenocarcinoma.
T. Kawai (1991)
10.2486/INDHEALTH.40.175
Assessment of the mutations of p53 suppressor gene and Ha- and Ki-ras oncogenes in malignant mesothelioma in relation to asbestos exposure: a study of 12 American patients.
F. Kitamura (2002)
10.1002/jso.2930110302
Malignant mesothelioma presenting in the pleura and peritoneum.
N. Mischler (1979)
Molecular analyses, morphology and immunohistochemistry together differentiate pleural synovial sarcomas from mesotheliomas: clinical implications.
M. Carbone (2002)
10.1097/00022744-199706000-00001
Extraskeletal Myxoid Chondrosarcoma: An Immunohistochemical Reappraisal of 39 Cases
A. Tos (1997)
10.1046/j.1365-2303.2000.00211.x
Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma and mesotheliosis: stepwise logistic regression analysis
A. Dejmek (2000)
10.1002/DC.10011
Malignant pleural effusions due to small‐cell lung carcinoma: A cytologic and immunocytochemical study
D. Chhieng (2001)
10.1093/jnci/63.5.1121
Human lung tumor-associated antigens of 32,000 daltons molecular weight.
D. Kempner (1979)
10.1038/modpathol.3880635
Primary Effusion Lymphoma: Cytopathologic Diagnosis Using In Situ Molecular Genetic Analysis for Human Herpesvirus 8
P. Wakely (2002)
10.1046/J.1365-2559.2003.01555.X
Unusual intraparenchymal growth patterns of malignant pleural mesothelioma.
N. Nind (2003)
[Histochemical and immunohistochemical methods in the diagnosis of mesothelioma].
Ernesto Sergio Bertoldo (1987)
10.1016/j.humpath.2009.06.014
Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.
J. Bishop (2010)
10.1111/j.1440-1827.1992.tb01878.x
Diagnostic criteria for human diffuse malignant mesothelioma.
Y. Suzuki (1992)
10.1043/1543-2165(2008)132[397:AOITTD]2.0.CO;2
Application of immunohistochemistry to the diagnosis of malignant mesothelioma.
A. Marchevsky (2008)
10.1043/0003-9985(2001)125<1588:UCCVOE>2.0.CO;2
Unusual clear cell variant of epithelioid mesothelioma.
E. Dessy (2001)
10.1016/S0378-4274(01)00507-0
Lung diseases due to environmental exposures to erionite and asbestos in Turkey.
S. Emri (2002)
10.1002/path.1711650408
Immunohistochemical positivity for neuron-specific enolase and Leu-7 in malignant mesotheliomas.
F. Mayall (1991)
10.1097/00129039-200206000-00001
Thyroid Transcription Factor-1: A Review
S. Lau (2002)
10.1016/S0344-0338(96)80208-1
The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type.
V. Gotzos (1996)
10.1016/J.HUMPATH.2005.01.019
D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma.
N. Ordóñez (2005)
Hemangioendothelioma of the lung and pleura: report of three cases.
Ximenes M rd (1981)
10.1097/00000478-198206000-00003
Malignant mesothelioma: Ultrastructural distinction from adenocarcinoma
Michael J. Warhol (1982)
Loss of heterozygosity analysis defines a critical region in chromosome 1p22 commonly deleted in human malignant mesothelioma.
W. Lee (1996)
Immunocytology of body cavity fluids. MOC-31, a monoclonal antibody discriminating between mesothelial and epithelial cells.
T. Ruitenbeek (1994)
10.1002/(SICI)1097-0142(19991025)87:5<295::AID-CNCR9>3.0.CO;2-1
MOC‐31 aids in the differentiation of metastatic adenocarcinoma from hepatocellular carcinoma
T. Niemann (1999)
10.1093/ajcp/93.6.741
Mesothelial cell inclusions in mediastinal lymph nodes mimicking metastatic carcinoma.
J. Brooks (1990)
10.1378/chest.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1016/s0096-5588(20)30819-9
Localized pleural mesothelioma of epithelial type.
R. Yesner (1953)
10.1016/S1092-9134(98)80045-2
Adenocarcinoma simulating mesothelioma: a clinicopathologic and immunohistochemical study of 29 cases.
M. Koss (1998)
10.1177/003591576605900125
Asbestos, asbestosis and mesothelioma of the pleura.
Smither Wj (1966)
10.1023/A:1005700508194
Genetics of renal tumours
S. Fleming (1997)
10.1183/09031936.01.17509220
The role of environmental and occupational exposures in Turkish immigrants with fibre-related disease.
P. Dumortier (2001)
10.1007/s102420200040
[Small-cell mesothelioma of the pleura: description of a case].
Alberto Cavazza (2002)
10.1038/modpathol.2008.45
Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas
S. Chiosea (2008)
10.1136/thx.43.5.366
Differentiation of malignant from normal and reactive mesothelial cells by the argyrophil technique for nucleolar organiser region associated proteins.
J. Ayres (1988)
10.1097/PAS.0b013e3181b6bde3
Tenascin-X is a Novel Diagnostic Marker of Malignant Mesothelioma
Y. Yuan (2009)
10.1002/jso.2930350107
Diagnostic histochemical and immunohistochemical studies in malignant mesothelioma.
J. Lucas (1987)
10.1097/PAI.0b013e318187dd26
Comparison of Different Clones (WT49 Versus 6F-H2) of WT-1 Antibodies for Immunohistochemical Diagnosis of Malignant Pleural Mesothelioma
K. Tsuta (2009)
10.5555/uri:pii:074025709290006U
Differential diagnosis between mesothelioma and adenocarcinoma: a multimodal approach based on ultrastructure and immunocytochemistry.
C. Bedrossian (1992)
10.1055/S-2007-979099
Characterization of the IGF system and analysis of the possible molecular mechanisms leading to IGF-II overexpression in a mesothelioma.
D. Hodzic (1997)
10.1136/thx.40.2.91
Comparison of tumour markers in malignant mesothelioma and pulmonary adenocarcinoma.
A. Gibbs (1985)
10.1007/s00428-001-0552-2
Value of thyroid transcription factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas: a study of 109 cases
J. Zámečnı́k (2001)
10.1097/PAP.0b013e3181915e94
D2-40 Immunohistochemistry—So Far!
A. Kalof (2009)
10.1136/jcp.25.7.577
Exfoliative cytology of diffuse mesothelioma
G. H. Roberts (1972)
[Pseudomesotheliomatous carcinoma of the lung].
R. Maeda (2007)
10.1111/J.1365-2559.2006.02442.X
Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports.
J. King (2006)
10.1043/1543-2165(2005)129[1421:DDOBAM]2.0.CO;2
Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies.
P. Cagle (2005)
p63 expression profiles in human normal and tumor tissues.
C. J. Di Como (2002)
10.1016/S0009-9260(99)91084-X
The CT appearance of pleural and extrapleural disease in lymphoma.
S. Aquino (1999)
10.1378/chest.111.1.106
The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
A. Renshaw (1997)
10.1097/00000478-200308000-00001
The Immunohistochemical Diagnosis of Mesothelioma: A Comparative Study of Epithelioid Mesothelioma and Lung Adenocarcinoma
N. Ordóñez (2003)
A histochemical characterization of malignant tumour mucins as a possible aid in the identification of metastatic deposits.
Cook Hc (1973)
10.1080/00313029500169362
Comparison Of Silver‐Staining Nucleolar Organizer Region (Agnor) Counts And Proliferating Cell Nuclear Antigen (Pcna) Expression In Reactive Mesothelial Hyperplasia And Malignant Mesothelioma
P. Bethwaite (1995)
10.1016/0046-8177(95)90145-0
CD-34 and keratin expression distinguishes solitary fibrous tumor (fibrous mesothelioma) of pleura from desmoplastic mesothelioma.
A. Flint (1995)
10.1002/1097-0142(19920901)70:5<1183::AID-CNCR2820700526>3.0.CO;2-O
Familial mesothelioma. Details of 17 cases with histopathologic findings and mineral analysis
A. Dawson (1992)
10.1136/jcp.25.6.557-b
'Retention lung' in infants.
J. Emery (1972)
10.1073/pnas.88.3.931
cDNA cloning and sequencing of human fibrillarin, a conserved nucleolar protein recognized by autoimmune antisera.
J. Aris (1991)
10.1097/00000478-199910000-00012
Benign mesothelial cells in mediastinal lymph nodes.
V. Parkash (1999)
10.1007/PL00002168
[Pleural mesothelioma. I: History, epidemiology, clinical aspects (symptoms, diagnosis)].
Wolfgang Neumeister (2001)
10.1378/chest.109.1.109
Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas.
L. Johansson (1996)
Diffuse malignant mesothelioma of the pleural space and its management.
L. Zellos (2002)
10.1111/J.1440-1843.2005.00765.X
Clinicopathological analysis of lung cancer resembling malignant pleural mesothelioma.
Y. Kobashi (2005)
10.1309/48KC-17WA-U69B-TBXQ
Expression of T/NK-cell and plasma cell antigens in nonhematopoietic epithelioid neoplasms. An immunohistochemical study of 447 cases.
P. Chu (2003)
10.1007/978-3-642-41193-9_11
Analysis of Tissue Mineral Fiber Content
V. Roggli (2004)
10.1097/00000478-200206000-00010
TTF-1 Expression in Pulmonary Adenocarcinomas
Y. Yatabe (2002)
New therapies in the treatment of malignant pleural mesothelioma.
L. Kaiser (1997)
10.1089/02724570050031167
Breast cancer progression and expression of blood group-related tumor-associated antigens.
K. Steplewska-Mazur (2000)
10.1136/jcp.2008.061887
An EMA negative, desmin positive malignant mesothelioma: limitations of immunohistochemistry?
W D Salman (2009)
10.1002/path.1711560414
Demonstration of AgNOR-related proteins in microwave-fixed tissues.
A. Leong (1988)
10.1080/028418501127347070
Evaluation of pleural disease using MR and CT: With special reference to malignant pleural mesothelioma
A. Knuuttila (2001)
10.1111/j.1600-0463.2009.02461.x
Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40
S. Daugaard (2009)
10.1002/1097-0142(19850815)56:4<905::AID-CNCR2820560435>3.0.CO;2-U
The malignant pleural effusion. A review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients
W. W. Johnston (1985)
10.1309/AJCPWFW7O1FVFLKT
Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids.
J. Shen (2009)
10.1002/1097-0142(19880815)62:4<838::AID-CNCR2820620433>3.0.CO;2-9
Mesothelioma of childhood
A. Fraire (1988)
10.1097/01.pai.0000213148.62525.9a
Evidence-based Guidelines for the Utilization of Immunostains in Diagnostic Pathology: Pulmonary Adenocarcinoma Versus Mesothelioma
A. Marchevsky (2007)
Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux.
A. Cohen (1996)
10.1292/jvms1939.52.1313
Histological classification of 62 spontaneous mesotheliomas in F344 rats.
K. Shibuya (1990)
10.1097/PAS.0b013e3181da7687
PAX8 Reliably Distinguishes Ovarian Serous Tumors From Malignant Mesothelioma
Anna R. Laury (2010)
10.1165/ajrcmb.12.5.7742009
The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma.
D. FitzPatrick (1995)
10.1097/00000478-200404000-00013
Well-differentiated Papillary Mesothelioma of the Pleura: A Series of 24 Cases
F. Galateau-Sallé (2004)
10.1016/j.pathol.2016.03.005
Loss of expression of BAP1 is very rare in non-small cell lung carcinoma.
Juliana Andrici (2016)
10.1043/1543-2165-133.8.1317
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
A. Husain (2009)
10.1111/j.1365-2559.1996.tb01393.x
Mesothelioma-binding antibodies: thrombomodulin, OV 632 and HBME-1 and their use in the diagnosis of malignant mesothelioma.
R. Attanoos (1996)
10.1016/j.ejcts.2009.08.027
Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma.
Alexandra Schramm (2010)
Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.
T. Kawai (1988)
10.1016/S0272-5231(01)00002-8
Thoracic and lung involvement in familial Mediterranean fever (FMF).
M. Lidar (2002)
10.1078/0344-0338-00043
Immunohistochemical MIB-1 and p27kip1 as prognostic factors in pleural mesothelioma.
E. Leonardo (2001)
10.1046/j.1365-2559.1996.d01-500.x
Thrombomodulin as a marker of vascular and lymphatic tumours.
M. Appleton (1996)
Effusion cytology in the diagnosis of malignant epithelioid and biphasic pleural mesothelioma.
M. Sherman (1990)
10.1097/00000478-199004000-00010
Pleural multicystic mesothelial proliferation. The so-called multicystic mesothelioma.
N. Ball (1990)
10.1097/00000478-200010000-00021
Deciduoid epithelial mesothelioma of the pleura with focal rhabdoid change.
L. Puttagunta (2000)
10.1016/S0304-3835(98)00142-6
Familial pleural malignant mesothelioma: clustering in three sisters and one cousin.
V. Ascoli (1998)
10.1002/cncr.23413
9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA‐ICM, and AgNOR analysis
F. Onofre (2008)
10.18632/oncotarget.10653
Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma
M. Carbone (2016)
10.1309/7ECY-KN61-PP1M-52EB
Lymphohistiocytoid mesothelioma. An often misdiagnosed variant of sarcomatoid malignant mesothelioma.
H. Khalidi (2000)
10.1002/(SICI)1097-0142(19980425)84:2<101::AID-CNCR6>3.0.CO;2-S
Utility of the antibodies CA 19‐9, HBME‐1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology
P. Fetsch (1998)
10.1038/modpathol.3800827
Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin?
G. Tong (2007)
10.1136/jclinpath-2013-201609
Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA
D. Henderson (2013)
10.1016/0304-3835(96)04172-9
Parental cancer and genetic predisposition in malignant pleural mesothelioma: a case-control study.
M. Huncharek (1996)
10.1097/00000478-199009000-00003
Lymph Node Metastasis: as the Initial Manifestation of Malignant Mesothelioma Report of Six Cases
J. Sussman (1990)
10.1038/modpathol.3880018
Value of the Mesothelium-Associated Antibodies Thrombomodulin, Cytokeratin 5/6, Calretinin, and CD44H in Distinguishing Epithelioid Pleural Mesothelioma from Adenocarcinoma Metastatic to the Pleura
P. Cury (2000)
10.1097/00000478-198904000-00003
The Immunohistochemical Diagnosis of Mesothelioma: Differentiation of Mesothelioma and Lung Adenocarcinoma
N. Ordóñez (1989)
10.1034/j.1600-0463.2003.11101251.x
Growth regulatory factors and signalling proteins in testicular germ cell tumours
M. Devouassoux-Shisheboran (2003)
10.1177/030089160208800523
Non-asbestos related diffuse malignant mesothelioma.
M. Huncharek (2002)
10.1007/bf02890064
Expression of keratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas
R. Moll (1989)
10.1016/S0046-8177(99)90011-4
The immunohistochemical diagnosis of epithelial mesothelioma.
N. Ordóñez (1999)
10.1097/00000478-199712000-00003
The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval.
J. R. Riera (1997)
10.1177/003591576605900126
Mortality among asbestos workers.
I. D. Hill (1966)
Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas.
J. Corson (1982)
10.1016/s0169-5002(87)80458-0
Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
K. Sheibani (1986)
10.1046/j.1365-2559.1997.5370782.x
Pseudomesotheliomatous angiosarcoma: a pleuropulmonary lesion simulating malignant pleural mesothelioma.
G. Falconieri (1997)
10.1111/j.1600-0560.1992.tb01602.x
Distant cutaneous metastasis of pleural malignant mesothelioma
P. Dutt (1992)
10.1016/S0037-198X(98)80038-2
Case of the season
B. Golla (1998)
10.1002/dc.23491
BAP1 Immunostain and CDKN2A (p16) FISH Analysis
A. Walts (2016)
Pathology of diffuse malignant pleural mesothelioma.
J. Corson (1997)
10.1016/j.jtho.2015.10.003
Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma
A. Billè (2016)
10.1016/S1092-9134(99)80042-2
Pseudomesotheliomatous carcinoma involving pleura and peritoneum: A clinicopathologic and immunohistochemical study of three cases.
I. Shah (1999)
10.3109/00313028009086812
MALIGNANT MESOTHELIOMA: A REVIEW OF 35 CASES WITH DIAGNOSIS AND PROGNOSIS
M. Griffiths (1980)
10.1016/j.cancergen.2016.07.002
Mesothelioma families without inheritance of a BAP1 predisposing mutation.
Valeria Ascoli (2016)
Early diagnosis of mesothelioma in serous effusions using AgNOR analysis.
N. Pomjanski (2001)
10.1016/0273-2300(91)90018-Q
Background incidence of mesothelioma: animal and human evidence.
E. B. Ilgren (1991)
10.1309/8X4T-35B7-7529-QE7X
WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms.
N. Goldstein (2001)
10.3109/00313020903493971
Sarcomatoid localised mesothelioma mimicking intrapulmonary synovial sarcoma: a case report and review of the literature.
Angeline Teo (2010)
10.1097/00000478-200006000-00006
Epithelial mesothelioma with deciduoid features: report of four cases.
N. Ordóñez (2000)
10.1309/XL6K-8E62-9FLD-V8Q8
Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.
F. Roberts (2001)
10.1200/JCO.1996.14.7.2098
Malignant mesothelioma following treatment for Hodgkin's disease.
L. Weissmann (1996)
10.1046/J.1365-2559.2000.00770.X
HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma.
J. Oates (2000)
10.1002/DC.20208
The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: A comparative study
R. Saad (2005)
10.1002/dc.2840060104
“Thick” cell membranes revealed by immunocytochemical staining: A clue to the diagnosis of mesothelioma
A. Leong (1990)
10.1002/DC.2039
Absence of SV‐40 large T antigen (Tag) in malignant mesothelioma effusions: An immunocytochemical study
A. Simsir (2001)
10.1002/1097-0142(19910201)67:3<655::AID-CNCR2820670322>3.0.CO;2-J
Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma
Patricia R. Wirth (1991)
10.1016/J.HUMPATH.2006.11.016
Immunohistochemical detection of antiapoptotic protein X-linked inhibitor of apoptosis in mammary carcinoma.
S. Jaffer (2007)
10.1002/jcb.240630509
In vitro and in vivo studies of mesothelioma.
H. Pass (1996)
Neoplasms composed of eosinophilic polygonal cells: an overview with consideration of different cytomorphologic patterns.
O. Nappi (1999)
10.1016/J.EJCTS.2007.09.043
Localised malignant pleural mesothelioma: a separate clinical entity requiring aggressive local surgery.
A. Nakas (2008)
10.1007/BF00713385
Immunohistochemistry in the diagnosis of malignant mesothelioma
M. Pfaltz (2004)
10.5555/uri:pii:074025709290007V
Malignant mesothelioma: cytologic diagnosis with histologic, immunohistochemical, and ultrastructural correlation.
A. Leong (1992)
10.3109/01913128509074586
Sarcomatoid pleural mesothelioma.
S. Hammar (1985)
10.1111/J.1440-1827.2007.02080.X
Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
K. Kushitani (2007)
10.1292/jvms1939.51.327
An ultrastructural study of malignant mesotheliomas in two cows.
N. Hashimoto (1989)
10.1111/J.1365-2559.2004.01928.X
The pathology associated with therapeutic procedures in malignant mesothelioma.
R. Attanoos (2004)
The pathology of benign and malignant pleural disease.
Hammar Sp (1994)
10.1097/PAS.0b013e31814faacf
Podoplanin is a Better Immunohistochemical Marker for Sarcomatoid Mesothelioma Than Calretinin
Diana M Padgett (2008)
10.1292/jvms.56.403
Tumors in domestic animals examined during a ten-year period (1980 to 1989) at Miyazaki University.
M. Rostami (1994)
10.1046/j.1365-2559.1996.d01-562.x
Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression.
A. Bateman (1997)
10.1093/ajcp/102.3.331
Biphasic and monophasic sarcomatoid carcinomas of the lung. A reappraisal of 'carcinosarcomas' and 'spindle-cell carcinomas'.
O. Nappi (1994)
10.1002/(SICI)1097-0215(19981005)78:2<182::AID-IJC11>3.0.CO;2-D
Constitutive expression of the Wilms tumor suppressor gene (WT1) in renal cell carcinoma.
C. Campbell (1998)
10.1016/S0304-3835(98)00096-2
p53 may mediate the mdr-1 expression via the WT1 gene in human vincristine-resistant leukemia/lymphoma cell lines.
M. Hirose (1998)
10.1002/dc.21340
Podoplanin is a useful marker for identifying mesothelioma in malignant effusions
Atef N Hanna (2010)
10.1016/0959-8049(95)00365-P
Genetic factors in the aetiology of malignant mesothelioma.
M. Huncharek (1995)
[Malignant mesothelioma of the pleura among women].
C. Bianchi (2004)
10.1046/J.1440-1827.2001.01279.X
Localized pleural malignant mesothelioma.
S. Erkılıç (2001)
10.1016/S0720-048X(00)00168-6
Malignant pleural disease.
B. Feragalli (2003)
10.1007/s00432-008-0444-9
Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors
Shoshana J. Weiner (2008)
10.1097/00000478-199609000-00001
Calretinin: a novel immunocytochemical marker for mesothelioma.
C. Doglioni (1996)
A light and electron microscopic study of lung cancers: clinical implications
Chen Hp (1993)
10.1016/s0169-5002(87)80457-9
The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3).
C. Szpak (1986)
10.1309/TWCQV536WWRNEU51
Prognostic role of osteopontin expression in malignant pleural mesothelioma.
S. Cappia (2008)
10.1097/00000478-199810000-00006
Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
N. Ordóñez (1998)
10.1093/ANNHYG/MEG048
Exposure to brake dust and malignant mesothelioma: a study of 10 cases with mineral fiber analyses.
K. Butnor (2003)
10.1046/J.1440-1827.2002.01357.X
Microcystic variant of localized malignant mesothelioma accompanying an adenomatoid tumor-like lesion.
H. Umezu (2002)
10.1111/j.1751-0813.1992.tb09889.x
Mesothelioma in horses.
C. Colbourne (1992)
10.1016/S0025-6196(12)65411-1
Malignant mesothelioma of the pleura.
R. J. Pisani (1988)
10.1002/cncy.20071
The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions
F. Hasteh (2010)
10.1002/(SICI)1097-0142(19990101)85:1<250::AID-CNCR41>3.0.CO;2-3
The use of epithelial membrane antigen and silver‐stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses
K. Metze (1999)
10.1002/(SICI)1097-0142(19960401)77:7<1379::AID-CNCR24>3.0.CO;2-Y
Post‐irradiation malignant mesothelioma
A. Cavazza (1996)
10.1046/J.1365-2559.2003.01583.X
Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.
D. Lucas (2003)
10.1007/BF01069743
Immunoreactivity for bcl-2 protein in malignant mesothelioma and non-neoplastic mesothelium.
K. Segers (1994)
10.1043/0003-9985(2000)124<0609:HMCIML>2.0.CO;2
Hyperplastic mesothelial cells in mediastinal lymph node sinuses with extranodal lymphatic involvement.
P. Isotalo (2000)
10.1016/0046-8177(92)90235-U
Cytokeratin expression in adrenocortical neoplasia: an immunohistochemical and biochemical study with implications for the differential diagnosis of adrenocortical, hepatocellular, and renal cell carcinoma.
M. Gaffey (1992)
10.1016/S0003-4975(99)01038-3
Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.
V. Rusch (1999)
10.1016/S0009-9260(05)80356-3
Case report: Pleural granulocytic sarcoma: CT characteristics
M. J. Lee (1991)
10.1016/S0344-0338(84)80063-1
Keratins in malignant mesotheliomas and pleural adenocarcinomas: comparative immunohistochemical analysis with polyclonal and monoclonal antibodies.
F. Bejui-Thivolet (1984)
Fine needle aspiration cytology of malignant mesothelioma.
G. Sterrett (1987)
10.1177/030089169007600613
Thrombocytosis in Malignant Pleural Mesothelioma
V. de Pangher Manzini (1990)
10.1016/S0720-048X(01)00426-0
Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases.
M. Metintas (2002)
10.1111/his.12089
Well-differentiated papillary mesothelioma: a clinicopathological and immunohistochemical study of 18 cases with additional observation.
X. Chen (2013)
Clear cell tumors of the lower respiratory tract.
M. Gaffey (1997)
10.1097/01.MP.0000073134.60541.E8
The Role of Calretinin, Inhibin, Melan-A, BCL-2, and C-kit in Differentiating Adrenal Cortical and Medullary Tumors: An Immunohistochemical Study
Paul J. Zhang (2003)
10.4103/0377-4929.125389
Pleural multicystic mesothelial proliferation: a mimicker of benign peritoneal mesothelioma.
Swati Agarwal (2013)
10.1007/BF01606427
Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: immunohistochemical findings
H. Moch (2005)
10.1378/CHEST.116.SUPPL_3.444S
Mesothelioma clinical presentation.
R. Bueno (1999)
10.1002/1097-0142(197304)31:4<869::AID-CNCR2820310416>3.0.CO;2-S
Primary malignant mesothelial tumors in canada, 1960–1968. A pathologic review by the mesothelioma panel of the canadian tumor reference centre
A. McDonald (1973)
10.1093/AJCP/110.2.135
The diagnosis of desmoplastic malignant mesothelioma.
T. Colby (1998)
10.1002/dc.2840110309
Markers for metastatic adenocarcinoma in serous effusion specimens
P. Shield (1994)
10.1111/j.1349-7006.2003.tb01432.x
Overexpression of the Wilms' tumor gene WT1 in human bone and soft‐tissue sarcomas
T. Ueda (2003)
10.3109/01913129609016314
Diagnosis of an anemone cell tumor as a B-cell lymphoma by molecular analysis.
K. Blakolmer (1996)
10.1016/j.lungcan.2009.10.004
Well-differentiated papillary mesothelioma with invasion to the chest wall.
Ikuko Torii (2010)
10.1002/ajim.4700220103
Primary neoplasms of the pleura. A report of five cases.
P. Klemperer (1992)
10.1016/S0344-0338(82)80007-1
Ultrastructural diagnosis of pleural tumors.
P. Stoebner (1982)
10.1136/oem.17.4.260
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
J. Wagner (1960)
10.1016/S1010-7940(99)00323-1
Mesothelioma--VATS biopsy and lung mobilization improves diagnosis and palliation.
M. Grossebner (1999)
10.1309/48KC17WAU69BTBXQ
Expression of T/NK-Cell and Plasma Cell Antigens in Nonhematopoietic Epithelioid Neoplasms
P. Chu (2003)
Nonrandom chromosome alterations in human malignant mesothelioma.
N. Popescu (1988)
10.1046/J.1365-2559.2002.01422.X
Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.
R. Attanoos (2002)
10.1097/00000478-199404000-00004
Localized Malignant Mesothelioma: A Clinicopathologic and Flow Cytometric Study
T. Crotty (1994)
Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens--evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor.
M. Miettinen (1994)
10.1038/modpathol.3880312
Immunohistochemical Diagnosis of Papillary Thyroid Carcinoma
C. Cheung (2001)
10.1046/J.1365-2559.2000.00981.X
Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms.
R. Attanoos (2000)
10.1097/00000478-200105000-00007
Calretinin and Other Mesothelioma Markers in Synovial Sarcoma: Analysis of Antigenic Similarities and Differences With Malignant Mesothelioma
M. Miettinen (2001)
10.1016/S0046-8177(98)90006-5
Ultrastructural features of diffuse malignant mesotheliomas.
T. Oury (1998)
10.1002/(SICI)1097-0142(19970901)80:5<948::AID-CNCR17>3.0.CO;2-W
Incidence of malignant pleural mesothelioma after thoracic radiotherapy
A. Neugut (1997)
10.1002/1097-0142(196604)19:4<521::AID-CNCR2820190407>3.0.CO;2-J
Mesothelioma associated with asbestosis. A report of 3 cases
R. Mann (1966)
10.1136/jcp.55.9.662
Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies
A. S. Abutaily (2002)
10.1002/DC.20747
Utility of WT‐1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions
Robert T. Pu (2008)
10.1016/S0046-8177(03)00177-1
Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas.
H. Frierson (2003)
10.1097/JTO.0b013e3181a8c874
Localized malignant pleural mesothelioma: report of two cases.
Silvia Tanzi (2009)
10.7326/0003-4819-96-6-746
Diffuse malignant mesothelioma. Prospective evaluation of 69 patients.
A. Chahinian (1982)
10.1046/J.1365-2559.2002.01527.X
The value of 'mesothelium-associated' antibodies in distinguishing between metastatic renal cell carcinomas and mesotheliomas.
M. Osborn (2002)
10.1080/01913120252959227
Malignant Mesothelioma and Occupational Exposure to Asbestos: A Clinicopathological Correlation of 1445 Cases
V. Roggli (2002)
10.1200/jco.1993.11.6.1172
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.
D. Sugarbaker (1993)
10.3109/01913129609016331
Mucin-positive epithelial mesotheliomas: a histochemical, immunohistochemical, and ultrastructural comparison with mucin-producing pulmonary adenocarcinomas.
S. Hammar (1996)
10.3109/15513819209023314
Mesothelial and related neoplasms in children and adolescents: a clinicopathologic and immunohistochemical analysis of eight cases.
C. Coffin (1992)
10.1097/00000478-199108000-00008
Ber‐EP4 Antibody as a Discriminant in the Differential Diagnosis of Malignant Mesothelioma Versus Adenocarcinoma
K. Sheibani (1991)
[Cytodiagnosis of pleural mesotheliomas].
G Castelain (1969)
10.1097/JTO.0b013e3181a97dc3
Pleural well-differentiated papillary mesothelioma: a case report.
Steven Kao (2009)
10.1309/LX7NFRDXY1JQF9R1
Immunohistochemical detection of XIAP in mesothelium and mesothelial lesions.
M. Wu (2007)
Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
P. Illei (2003)
10.1016/j.anndiagpath.2007.10.003
Immunohistochemical approaches to the diagnosis of undifferentiated malignant tumors.
M. Wick (2008)
10.2307/3580117
The german thorotrast study: recent results and assessment of risks.
G. van Kaick (1999)
Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach.
DeYoung Br (2000)
10.1097/00001622-200303000-00005
Indications and limitations of radiotherapy in malignant pleural mesothelioma
S. Senan (2003)
10.1111/j.1440-1827.2009.02459.x
Pleural malignant mesothelioma with invasive micropapillary component and its association with pulmonary metastasis.
Ai Mogi (2009)
Simian virus 40 and pleural mesothelioma in humans.
H. Strickler (1996)
10.1093/ANNHYG/45.7.513
Case-referent survey of young adults with mesothelioma: I. Lung fibre analyses.
J. C. Mcdonald (2001)
10.1016/S0169-5002(03)00120-X
Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4.
V. Villena (2003)
10.1097/00000478-199612000-00001
Malignant vascular tumors of the serous membranes mimicking mesothelioma. A report of 14 cases.
B. T. Lin (1996)
10.1002/dc.21128
Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens
Noriko Kimura (2009)
10.1002/gcc.10127
Molecular genetic characterization of the EWS/CHN and RBP56/CHN fusion genes in extraskeletal myxoid chondrosarcoma
I. Panagopoulos (2002)
Expression of epithelial membrane antigen on malignant mesothelioma cells. An immunocytochemical and immunoelectron microscopic study.
T. H. van der Kwast (1988)
Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma.
N. Shivapurkar (1999)
10.1007/s00428-006-0226-1
Nodular glomeruloid pleuroblastoma: a biphasic pleural-based malignant tumor with immature elements
Pinias Mukonoweshuro (2006)
10.1002/IJC.22425
SV40 and human cancer: a review of recent data.
K. Shah (2007)
10.1007/S11864-000-0047-4
Malignant pleural mesothelioma
H. Kindler (2000)
10.1053/SONC.2002.30237
The epidemiology of mesothelioma.
M. Britton (2002)
10.1093/oxfordjournals.qjmed.a067473
The clinical aspects of mesothelioma.
P. Elmes (1976)
10.1097/00063198-199909000-00011
Pulmonary associations in familial Mediterranean fever.
A. Livneh (1999)
10.1002/path.1711550206
The effect of a series of fixatives on the AgNOR technique.
P. Smith (1988)
10.1038/sj.bjc.6690816
Deletions at 14q in malignant mesothelioma detected by microsatellite marker analysis
A-M Björkqvist (1999)
10.1043/1543-2165(2008)132[1104:PST]2.0.CO;2
Pulmonary sarcomatous tumors.
Leslie Anne Litzky (2008)
10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0
Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression.
S. Kumar-Singh (1999)
Malignant sarcomatoid mesothelioma of the pleura: a histological and immunohistological study of a case.
Claudio Avellini (1991)
10.1016/0169-5002(93)90383-9
Detection of bone marrow metastases in small cell lung cancer patients. Comparison of immunologic and morphologic methods.
K. Beiske (1992)
10.1016/S0344-0338(11)80660-6
Small cell carcinoma of lung simulating pleural mesothelioma. Report of 4 cases with autopsy confirmation.
G. Falconieri (1995)
Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization.
M. Dreyling (1995)
10.3109/01913128709048446
Diffuse epithelial mesothelioma: a review of the ultrastructural spectrum.
I. Dardick (1987)
10.1136/THX.2007.085241
EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors
H. Kothmaier (2007)
10.1093/ajcp/98.2.175
Distribution of CA 125 in adenocarcinomas. An immunohistochemical study of 481 cases.
T. S. Loy (1992)
10.1043/0003-9985(2003)127<193:IASOCT>2.0.CO;2
Incidence and significance of cytoplasmic thyroid transcription factor-1 immunoreactivity.
P. Bejarano (2003)
10.1111/j.1600-0463.2001.tb00011.x
ABH and Lewis histo‐blood group antigens in cancer
J. Pendu (2001)
10.1038/modpathol.2009.180
Sarcomatoid mesothelioma: a clinical–pathologic correlation of 326 cases
S. Klebe (2010)
10.1093/AJCP/110.2.191
The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining.
W. E. Mangano (1998)
10.1002/dc.21146
Evidence‐based guidelines to optimize the selection of antibody panels in cytopathology: Pleural effusions with malignant epithelioid cells
Danielle E Westfall (2010)
10.1016/S0046-8177(88)80005-4
Adenocarcinoma of the lung: a comparative diagnostic study using light and electron microscopy.
D. Mcgregor (1988)
[PRIMARY NEOPLASMS OF THE PLEURA].
J. Lemercier (1963)
10.1093/ajcp/97.4.498
Extraskeletal myxoid chondrosarcoma of the pleura. Report of a case clinically simulating mesothelioma.
S. P. Goetz (1992)
10.7326/0003-4819-87-5-613
Pleural mesothelioma: clinical features and therapeutic implications.
S. Legha (1977)
10.1097/00000478-200110000-00012
Well-Differentiated Papillary Mesothelioma
K. Butnor (2001)
10.1309/AJCPT94JVWIHBKRD
Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
D. Wu (2013)
10.3109/01913129609023233
The role of ultrastructural pathology in the diagnosis of epithelial and unusual renal tumors.
G. Herrera (1996)
10.1136/jcp.43.3.213
Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial.
U. Latza (1990)
p53 immunostaining in differential diagnosis of pleural mesothelial proliferations.
V. Esposito (1997)
10.1007/S002680020021
Treatment of Malignant Mesothelioma
M. Jaklitsch (2001)
10.1046/J.1365-2559.2003.01685.X
Synchronous diffuse malignant mesothelioma and carcinomas in asbestos-exposed individuals.
R. Attanoos (2003)
10.1097/00022744-200212000-00008
Immunohistochemical Profile of Common Epithelial Neoplasms Arising in the Kidney
M. Kim (2002)
10.1046/J.1365-2559.2003.01686.X
The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2.
R. Attanoos (2003)
10.1164/arrd.1975.111.5.699
Histochemical demonstration of hyaluronic acid in a case of pleural mesothelioma.
H. Arai (1975)
10.1016/j.ejca.2010.01.032
TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t(X;18): analysis of 319 cases.
T. Knösel (2010)
10.1136/oem.43.1.18
Asbestos content of lung tissue in asbestos associated diseases: a study of 110 cases.
V. Roggli (1986)
10.1097/PAS.0b013e31802baad7
Lymphohistiocytoid Variant of Malignant Mesothelioma of the Pleura: A Series of 22 Cases
F. Galateau-Sallé (2007)
10.1097/00000478-199206000-00007
Immunoreactivity for BER‐EP4 in Adenocarcinomas, Adenomatoid Tumors, and Malignant Mesotheliomas
M. Gaffey (1992)
10.1111/j.1749-6632.1979.tb18735.x
MESOTHELIOMA ON THE COAST OF BRITTANY, FRANCE
M. Lajartre (1979)
Malignant mesothelioma of the pleura: clinical aspects and symptomatic treatment.
M. Law (1984)
10.1002/cncr.23254
Utility of anti‐L523S antibody in the diagnosis of benign and malignant serous effusions
K. Hanley (2008)
10.1002/dc.2840090106
Cytopathology of malignant mesothelioma: A study of its patterns and histological bases
Luigi Dibonito (1993)
10.1002/1097-0142(197211)30:5<1216::AID-CNCR2820300511>3.0.CO;2-5
Malignant mesothelioma in childhood. Report of 13 cases
G. Grundy (1972)
10.1016/S0046-8177(87)80196-X
The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: the role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen.
E. Cibas (1987)
10.1016/s0272-2712(18)30761-3
Tumors of serosal tissue origin.
J. W. Bolen (1987)
Diagnostic electron microscopy in gynecologic pathology.
Alex S Ferenczy (1979)
10.1038/modpathol.3800736
D2-40 and calretinin—a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation
Marc Hinterberger (2007)
10.1002/ijc.2910630304
Lung carcinoma and malignant mesothelioma in patients exposed to Thorotrast: incidence, histology and p53 status.
M. Andersson (1995)
10.1097/00000478-198810000-00001
Multicystic Mesothelioma: An Analysis of Pathologic Findings and Biologic Behavior in 37 Cases
S. Weiss (1988)
10.1007/s10014-009-0262-z
Expression of podoplanin and calretinin in meningioma: an immunohistochemical study
Masayuki Shintaku (2009)
10.1053/JCPA.2002.0563
Tumours in calves: comparative aspects.
W. Misdorp (2002)
10.1002/(SICI)1097-4652(199908)180:2<150::AID-JCP2>3.0.CO;2-H
Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma.
S. S. Murthy (1999)
Ultrastructure of human malignant diffuse mesothelioma.
Y. Suzuki (1976)
10.1038/modpathol.3800544
The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study
N. Ordóñez (2006)
10.1111/j.1440-1827.2008.02309.x
Pleomorphic carcinoma of the lung expressing podoplanin and calretinin.
H. Kenmotsu (2008)
10.1093/CARCIN/23.7.1127
Alterations of the p16(INK4) locus in human malignant mesothelial tumors.
T. Hirao (2002)
10.1043/1543-2165(2008)132[23:CMVBHU]2.0.CO;2
Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?
Virganeyce Lyons-Boudreaux (2008)
Utility of AgNOR technique in distinguishing reactive mesothelial hyperplasia, malignant mesothelioma and pulmonary adenocarcinoma.
Konanki Ramesh (1994)
Latent period for malignant mesothelioma of occupational origin.
B. Lanphear (1992)
10.1093/ajcp/86.5.566
Distinct keratin patterns demonstrated by immunoperoxidase staining of adenocarcinomas, carcinoids, and mesotheliomas using polyclonal and monoclonal anti-keratin antibodies.
H. Kahn (1986)
Primary pleuro-pulmonary malignant germ cell tumours.
P. Vaideeswar (2002)
10.1182/blood.V89.4.1405
Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia.
K. Inoue (1997)
10.1007/BF00496570
Histologic distinction between malignant mesothelioma, benign pleural lesion and carcinoma metastasis
W. Kwee (2004)
10.1378/CHEST.116.SUPPL_3.450S
Pleuropneumonectomy in the treatment of malignant pleural mesothelioma.
S. Grondin (1999)
10.1002/1097-0142(197305)31:5<1046::AID-CNCR2820310502>3.0.CO;2-P
Electron microscopy in the diagnosis of pleural mesotheliomas
N. Wang (1973)
10.1002/1097-0142(19850501)55:9<1968::AID-CNCR2820550923>3.0.CO;2-9
Malignant mesothelioma secondary to chronic inflammation and old scars. Two new cases and review of the literature
G. Hillerdal (1985)
10.1002/1097-0142(19820901)50:5<970::AID-CNCR2820500527>3.0.CO;2-Z
Epithelioid hemangioendothelioma a vascular tumor often mistaken for a carcinoma
S. Weiss (1982)
10.1007/s004320050171
Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma
E. Tolnay (1998)
10.1002/(SICI)1097-0339(199910)21:4<253::AID-DC5>3.0.CO;2-N
Cytopathology of malignant mesothelioma of the pleura in fine‐needle aspiration biopsy
G. Nguyen (1999)
10.1016/S0749-3797(18)31325-4
Familial clustering of mesothelioma: a report on three affected persons in one family.
T. Krousel (1986)
10.1007/s00428-008-0689-3
Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas
S. Dacic (2008)
Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian Mesothelioma Panel.
W. Mccaughey (1991)
10.1038/modpathol.3800543
Mesothelioma with rhabdoid features: an ultrastructural and immunohistochemical study of 10 cases
N. Ordóñez (2006)
10.1053/J.SEMDP.2003.08.005
Extramedullary hematopoietic proliferations, extraosseous plasmacytomas, and ectopic splenic implants (splenosis).
O. Nappi (2003)
10.1165/ajrcmb/8.2.214
Tumorigenic conversion of human mesothelial cells as a consequence of platelet-derived growth factor-A chain overexpression.
A. Van der Meeren (1993)
10.5858/arpa.2011-0039-RA
Mesothelioma not associated with asbestos exposure.
B. Jasani (2012)
10.1016/0165-4608(85)90128-1
Familial mesothelioma: review and family study.
Henry T. Lynch (1985)
10.1097/PAI.0b013e3181da8387
Value of D2-40 in the Differential Diagnosis of Pleural Neoplasms With Emphasis on Its Positivity in Solitary Fibrous Tumor
Y. Hu (2010)
10.1200/JCO.2002.09.021
Pyothorax-associated lymphoma: a review of 106 cases.
S. Nakatsuka (2002)
10.1111/J.1365-2559.2006.02496.X
Diagnostic value of markers M2A, OCT3/4, AP-2gamma, PLAP and c-KIT in the detection of extragonadal seminomas.
K. Biermann (2006)
10.1038/modpathol.2008.125
Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review
S. Klebe (2008)
10.1097/00000478-200101000-00004
Immunohistochemical Panels For Differentiating Epithelial Malignant Mesothelioma From Lung Adenocarcinoma: A Study With Logistic Regression Analysis
R. Carella (2001)
10.1136/vr.143.1.22
Pleural malignant mesothelioma in a captive clouded leopard (Neofelis nebulosa nebulosa)
A. Cunningham (1998)
10.2217/14622416.9.8.1069
The serine protease HtrA1 is a novel prognostic factor for human mesothelioma.
A. Baldi (2008)
10.6004/JNCCN.2012.0006
[Malignant pleural mesothelioma].
Q. Kong (1983)
10.1097/00125480-199801000-00051
In search of a positive immunohistochemical marker for mesothelioma: an update.
N. Ordóñez (1998)
10.1378/CHEST.124.3_SUPPL.26S
The protein C pathway.
C. Esmon (2000)
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
10.1177/030098586700400204
Mesothelioma in the Calf
A. Baskerville (1967)
10.3109/01913128809048477
The ultrastructure and histogenesis of male germ neoplasia with emphasis on seminoma with early carcinomatous features.
J. Srigley (1988)
10.1093/annhyg/38.4.561
The human evidence: parenchymal and pleural changes.
G. Hillerdal (1994)
10.1002/PATH.1312
Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium.
M. Gulyás (2003)
10.1046/J.1365-2559.2001.1217D.X
Deciduoid pleural mesothelioma.
H. Monaghan (2001)
[Malignant mesothelioma of the pleura following radiotherapy of Hodgkin disease].
L. Falchero (1996)
10.1043/0003-9985(2003)127<0465:MMDNDO>2.0.CO;2
Malignant mesothelioma does not demonstrate overexpression or gene amplification despite cytoplasmic immunohistochemical staining for c-Erb-B2.
A. Horvai (2003)
10.5555/uri:pii:0093775481900403
Clinical presentation and natural history of benign and malignant mesothelioma.
K. Antman (1981)
Simian virus 40 and human cancer.
L. Mutti (1998)
10.1002/1097-0142(19840715)54:2<367::AID-CNCR2820540232>3.0.CO;2-Y
Mesothelioma following Wilms' tumor in childhood
K. H. Antman (1984)
10.1002/1097-0142(19840901)54:5<951::AID-CNCR2820540536>3.0.CO;2-A
Non‐asbestos‐related malignant mesothelioma. A review
J. T. Peterson (1984)



Semantic Scholar Logo Some data provided by SemanticScholar